Merus initially surged on superior interim trial data, while Bicara Therapeutics tanked. Click here to find out why BCAX ...

Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...

India's digital infrastructure development has been a "game-changer", putting the country ahead of most other nations, ...

WASHINGTON — Trump administration officials are expected to release more details on their plan to lower prescription drug ...

Target has seen its business decline steadily for more than a year. It's not a massive drop, but it's enough of a decline ...

“Under no pressure and no response to any protest, they offered themselves a $2 billion commitment to the Black community and Black entrepreneurs, and then after the inauguration of Donald Trump, ...

Welcome to The Friday 5, Progressive Grocer’s weekly roundup of the top news and trends in the food retail industry. Each ...

Sometimes, it's better to wait before expanding a brand into retail. Here is why retail doesn’t build brands, it exposes them.

Tesla ( TSLA 5.66%) stock has tumbled 22% year to date amid a myriad of business and political headwinds, and Wall Street ...

President Donald Trump threatened to cut government contracts with Elon Musk amid feud, while the SpaceX CEO suggested decommissioning Dragon.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.